Keloids are not cancerous. They are benign growths of excess collagen that form at the site of a skin injury and sometimes spread beyond it, but they never metastasize to other organs the way true cancers do. Researchers have described keloids as “quasi-neoplastic” because they share a handful of unsettling traits with tumors, and population-level data suggests people who develop keloids may face a modestly higher risk of certain cancers. But a keloid itself is not a malignancy, and there is no documented pathway by which a keloid transforms into one.
Why Keloids Get Compared to Cancer
The comparison is understandable if you look at how keloids behave. Unlike a normal scar, which fills in a wound and then stops growing, a keloid keeps expanding outward past the original wound borders. It does not shrink on its own, and it comes back after treatment at very high rates. Those three features, progressive growth, no spontaneous regression, and frequent recurrence, are hallmarks that researchers associate with tumor biology rather than ordinary wound healing.1PubMed Central. Understanding Keloid Pathobiology From a Quasi-Neoplastic Perspective: Less of a Scar and More of a Chronic Inflammatory Disease With Cancer-Like Tendencies Some researchers have gone so far as to call keloids “benign dermal tumors” rather than scars, framing them as a chronic inflammatory disease with cancer-like tendencies.2PubMed. Keloid scarring or disease: Unresolved quasi-neoplastic tendencies in the human skin
At the cellular level, there are some overlapping mechanisms. Keloid fibroblasts show lower rates of programmed cell death compared to normal cells, which is one reason the tissue keeps piling up instead of self-regulating. Research has found that a protein called p53, which normally acts as a brake on cell growth and is famously mutated in many cancers, is dysregulated in certain areas of keloid tissue. At the same time, a protein called bcl-2 that blocks cell death is overexpressed in the younger, more active parts of a keloid.3PubMed. p53 and apoptosis alterations in keloids and keloid fibroblasts That combination, cells growing faster and dying less, sounds ominous. But the same research found that this pattern reverses in the older, more mature areas of the keloid, where cell death returns to normal. That built-in brake appears to prevent keloids from ever making the leap to malignancy.
Another shared pathway involves a growth signal called TGF-β, which is overactive in keloid tissue and also plays a role in certain cancers. In keloid fibroblasts, downstream signaling molecules that promote collagen production are ramped up, while the molecules that normally shut off that signal are suppressed.4PubMed. Transforming Growth Factor Beta Gene Signatures are Spatially Enriched in Keloid Tissue Biopsies and Ex vivo-Cultured Keloid Fibroblasts The result is excess collagen production, not the uncontrolled cell division that defines cancer. Sharing some molecular machinery with cancer does not make something cancerous, just as a car and a tank both have engines without being the same vehicle.
Do People With Keloids Face Higher Cancer Risk?
This is where the picture gets more interesting than a simple “no.” A large population-based study found that patients with keloids had roughly a one-and-a-half-fold higher overall risk of developing cancer compared to matched controls.5PubMed. Keloid revisited: Current concepts in treatment and differential diagnosis The same research group broke this down further and found that the link was strongest for skin cancer, where keloid patients had about 1.7 times the risk. Men with keloids were especially vulnerable, with roughly double the risk of skin cancer compared to men without keloids. For women with keloids, the elevated risk showed up for pancreatic cancer instead, at about twice the expected rate, and that association held even after adjusting for other known risk factors like diabetes and chronic pancreatitis.6Scientific Reports. Risk of cancer development in patients with keloids
These findings deserve some context. An association in epidemiological data does not mean that keloids cause cancer. It could mean that the same underlying tendency toward chronic inflammation or abnormal wound healing that produces keloids also creates an environment more hospitable to certain cancers. Chronic inflammation in the deep skin layer is thought to drive the invasive growth of keloids,7PubMed Central. Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis and chronic inflammation is a well-known cancer risk factor across many tissue types. There is also a genetic component: keloid formation runs in families and is far more common in certain ethnic groups, suggesting a strong hereditary predisposition.8PubMed Central. Keloid scarring: understanding the genetic basis, advances, and prospects Whether the same genetic variants that predispose someone to keloids also raise cancer susceptibility is an open question, not a settled one.
The practical takeaway is that a modest statistical elevation in cancer risk across a population does not mean your keloid is going to become cancerous. It means that whatever biological quirks make someone prone to keloids may overlap, in ways researchers are still working out, with factors that raise cancer risk in general. It is not a reason for panic, but it is worth mentioning to your doctor if you have keloids and a family history of cancer.
When Something That Looks Like a Keloid Is Actually Cancer
A more urgent concern than keloids becoming cancer is the possibility that what looks like a keloid was never a keloid in the first place. A rare skin cancer called dermatofibrosarcoma protuberans (DFSP) can closely mimic the appearance of a keloid, and case reports document patients treated surgically for a “keloid” that turned out to be DFSP on later pathological review.9PubMed Central. A Rare Case of Misdiagnosis: Recurrence of Dermatofibrosarcoma Protuberans That Was Treated Surgically as a Keloid DFSP is a slow-growing, locally aggressive tumor that develops in the skin’s connective tissue. It rarely spreads to distant organs, but it invades surrounding tissue and requires wide surgical margins to remove completely. Misdiagnosing it as a keloid and treating it with steroid injections or a simple shave excision can allow it to progress.
The risk of this mix-up is highest when the lesion is small (under two centimeters), when there is no clear history of an injury at the site, and when the growth is slow and seemingly benign. Early-stage DFSP can be especially hard to distinguish from a keloid on appearance alone.10PubMed Central. Dermatofibrosarcoma protuberans (DFSP) arising from a keloid scar – A case report This is one reason dermatologists sometimes recommend a biopsy for any raised scar that behaves unusually, grows faster than expected, or does not respond to standard keloid treatments. A biopsy is a simple procedure: a small tissue sample is removed and examined under a microscope, where the structural differences between DFSP and keloid tissue are generally clear. Keloid diagnosis is usually based on medical history combined with clinical signs such as pain, itching, redness, and firmness, and tissue biopsy and ultrasound are additional tools when the picture is not straightforward.11PubMed Central. Diagnosis and Treatment of Keloid: Method Summary and Effect Evaluation
If you have a raised scar that appeared without any preceding injury, is growing steadily, and does not itch or hurt the way keloids typically do, bring it to a dermatologist’s attention. The odds of it being DFSP are still very low, since DFSP is rare, but the consequences of a missed diagnosis are significant enough that a biopsy is worthwhile.
How Keloids Differ From Hypertrophic Scars
People often confuse keloids with hypertrophic scars, and the distinction matters because they behave differently and carry different implications. Both produce raised, thickened scar tissue after a wound, and they share enough features that even researchers debate where exactly the line falls. The key clinical difference is that hypertrophic scars stay within the borders of the original wound. They may be raised, red, and uncomfortable, but they do not expand outward. Keloids, by contrast, grow horizontally beyond the wound margins, and that spreading growth is the single strongest diagnostic feature that separates the two.12PubMed Central. Hypertrophic scars and keloids: Overview of the evidence and practical guide for differentiating between these abnormal scars
Under a microscope, keloid tissue contains thick, tightly packed collagen bundles that are significantly larger than those found in hypertrophic scars or normal skin.13PubMed Central. Morphological and immunochemical differences between keloid and hypertrophic scar Hypertrophic scars, on the other hand, tend to contain smaller collagen fibers organized in nodular clusters with tiny blood vessels running through them. Hypertrophic scars also frequently contain specialized cells called myofibroblasts that contract wound tissue, while keloids rarely do. Despite these differences, the distinctions are mostly a matter of degree rather than kind, and many of the same abnormalities show up in both. This is part of why the “quasi-neoplastic” label is applied to keloids specifically: their aggressive, spreading behavior pushes them further from normal scar biology and closer, at least superficially, to tumor-like growth patterns.
Cancer Drugs Used on Keloids
It can be alarming to learn that your dermatologist wants to inject a chemotherapy drug into your keloid. The drug most commonly used is 5-fluorouracil (5-FU), which is a cancer medication that blocks rapidly dividing cells. In keloid treatment, it is injected directly into the scar tissue at much lower doses than would be used for cancer, and it works by slowing down the overproductive fibroblasts that generate excess collagen. A systematic review found that roughly two-thirds of keloids treated with 5-FU alone achieved at least 50% improvement, with a relapse rate of about 16% at roughly half a year after treatment.14PubMed Central. Intralesional 5-Fluorouracil for Keloids: A Systematic Review Combining 5-FU with corticosteroid injections tends to produce even better results and lower recurrence rates.15PubMed Central. 5-Fluorouracil in the Treatment of Keloids and Hypertrophic Scars: A Comprehensive Review of the Literature
Other cancer-associated drugs used for keloids include bleomycin and mitomycin C, both of which work by different mechanisms to disrupt the overactive cells in scar tissue. Surgical removal followed by adjuvant chemotherapy injections has shown some of the lowest recurrence rates, with one review finding recurrence as low as 6% when surgery was combined with steroid injections and 19% when combined with 5-FU.16PubMed Central. The Use of Chemotherapeutics for the Treatment of Keloid Scars The use of these drugs does not mean keloids are cancer. It reflects the fact that the same cellular behaviors, rapid proliferation and resistance to normal growth controls, show up in both conditions, and drugs designed to counter those behaviors in cancer cells happen to work on overactive scar cells too.
Is Radiation Therapy for Keloids Safe?
Radiation is another treatment borrowed from cancer medicine that works well for stubborn keloids, especially after surgical removal. It targets the rapidly dividing cells at the wound site to prevent the keloid from growing back. Naturally, people worry that using radiation on the skin could cause cancer down the line. A critical review of the literature found that while radiation for keloids does come with acute and chronic side effects such as skin irritation and pigment changes, the risk of developing a secondary malignancy from the treatment is minimal.17PubMed. Radiation therapy modalities for keloid management: A critical review
An earlier review found only five reported cases in the medical literature where cancer developed after radiation therapy for keloids. These included cases of fibrosarcoma, basal cell carcinoma, thyroid cancer, and breast cancer, but in those cases it was unclear whether appropriate radiation doses were used or whether surrounding tissues were properly shielded.18PubMed. Is radiation therapy for keloids acceptable? The risk of radiation-induced carcinogenesis Modern radiation protocols for keloids use carefully controlled doses delivered to a small area, with shielding of nearby sensitive structures. Five cases across the entire medical literature, some with questionable dosing, puts this risk into perspective: it exists in theory but is vanishingly rare in practice. The much more immediate risk for most patients is leaving an aggressive keloid untreated and dealing with pain, restriction of movement, and psychological distress.
Where Keloids Tend to Form and Why
Keloids do not appear randomly. They have preferred locations: the earlobes, shoulders, upper chest, upper back, and jawline are the most common sites. Research has shown that these high-risk areas correspond to parts of the body where the skin experiences greater mechanical tension from everyday posture and movement. A study using biomechanical measurements found that changes in skin stiffness and thickness from postural shifts were most pronounced at sites where keloids commonly develop, and that these changes significantly predicted keloid distribution.19PubMed. Influence of mechanical skin tension and anatomical location on keloid scar initiation In other words, constant stretching and pulling of the skin at these sites appears to sustain the inflammatory signals that drive keloid growth.
This is also why ear piercings are such a common trigger: the earlobe is a high-tension site that gets a deliberate wound punched through it. Surgical incisions on the chest and shoulders are another frequent origin. Even minor injuries like acne lesions or insect bites can trigger keloids in susceptible individuals if they occur in these high-tension zones. The mechanical explanation helps clarify why keloids are rare on the scalp, palms, and soles, where skin tension dynamics are different.
A Disease Without an Animal Model
One reason keloid biology remains poorly understood is that keloids appear to be unique to humans. No other animal develops them naturally, which has severely limited researchers’ ability to study the disease.20PubMed Central. Keloids: Animal models and pathologic equivalents to study tissue fibrosis Scientists have tried various workarounds, including grafting human keloid tissue onto immunocompromised mice and creating transgenic mouse models, but none fully replicate the way keloids grow and recur in human skin.21PubMed Central. Animal Models for Studies of Keloid Scarring
This limitation matters practically because it slows the development of new therapies. Drug development for most diseases relies on testing treatments in animal models before moving to human trials, and without a reliable animal model, researchers have had to lean more heavily on cell cultures and small clinical studies. It also makes the cancer comparison interesting from an evolutionary angle: whatever genetic and inflammatory circuitry produces keloids is something our species carries alone. Whether this reflects something about human skin tension, our particular inflammatory response, or some other feature of human biology remains an open question. The lack of an animal model also means that large mechanistic questions, like exactly why keloid cells eventually stop short of malignant transformation despite sharing some molecular features with cancer cells, are harder to answer definitively. Research has identified that the blood vessel and lymphatic growth in keloid tissue responds to treatment in ways that do not predict outcomes, adding another layer of complexity.1PubMed Central. Understanding Keloid Pathobiology From a Quasi-Neoplastic Perspective: Less of a Scar and More of a Chronic Inflammatory Disease With Cancer-Like Tendencies Understanding keloids fully will likely require tools and approaches we have not developed yet, which is part of what makes the field frustrating and fascinating in equal measure.